Prostanoid and TP-receptors in atherothrombosis: Is there a role for their antagonism?

Summary

Atherosclerosis and its clinical manifestations (i.e. myocardial infarction, stroke) are major causes of mortality and morbidity in Western countries. Endothelial dysfunction is considered the first step in the cascade leading up to coronary events. Increasing evidence suggests that direct inhibition of thromboxane A₂/prostaglandin (TP)-receptors may not only have anti-platelet effects but also impact endothelial dysfunction as well as inflammatory component of atherosclerosis. While TP-receptor involvement in platelet function has received the greatest attention, more recent findings support the critical role of TP-receptor in other pathophysiological aspects of atherothrombosis. Prostanoids (i.e. TxA₂, F₂-isoprostanes, prostaglandins endoperoxides PGG₂/PGH₂) are known to promote the initiation and progression of atherosclerosis, not only via platelet activation, but through leukocyte-endothelial interactions and vasoconstriction. Dysfunctional endothelium, characterised by increased COX-activity, releases prostanoids that promote endothelial exposure to adhesion molecules and induce smooth muscle cell contraction. Plaque macrophages synthesise PGH₂/PGG₂ via COX-2; these potent prostanoids can trigger platelet activation and aggregation despite COX-1 inhibition by aspirin. TP-receptor inhibition has been reported to exert anti-atherosclerotic effects in pre-clinical model of disease. Reduction of plaque burden was associated with plaque stabilisation documented by the reduction in the content of macrophages, apoptotic cells, MMPs and endothelin-1, and the increase in smooth muscle cells content. TP-receptor blockade might have an anti-athero-sclerotic and plaque stabilisation effect. The possibility of combining anti-platelet activity with an anti-atherosclerotic effect via selective TP-receptor inhibitors could have important implications especially in clinical conditions associated with increased production of prostanoids, such as diabetes.

Keywords

Atherothrombosis - endothelial cells - platelet physiology - prostanoids - TP-receptors

• References

• 1 Fuster V, Voute J, Hunn M. et al. Low priority of cardiovascular and chronic diseases on the global health agenda: a cause for concern. Circulation 2007; 116: 1966-1970.
• 2 Ibanez B, Vilahur G, Badimon JJ. Plaque progression and regression in atherothrombosis. J Thromb Haemost 2007; 05 (Suppl. 01) 292-299.
• 3 Vanhoutte PM. Endothelial dysfunction: the first step toward coronary arteriosclerosis. Circ J 2009; 73: 595-601.
• 4 Fuster V, Moreno PR, Fayad ZA. et al. Atherothrombosis and high-risk plaque: part I: evolving concepts. J Am Coll Cardiol 2005; 46: 937-954.
• 5 Moore C, Tymvios C, Emerson M. Functional regulation of vascular and platelet activity during thrombosis by nitric oxide and endothelial nitric oxide synthase. Thromb Haemost 2010; 104: 342-349.
• 6 Giannarelli C, De Negri F, Virdis A. et al. Nitric oxide modulates tissue plasminogen activator release in normotensive subjects and hypertensive patients. Hypertension 2007; 49: 878-884.
• 7 Hutter R, Valdiviezo C, Sauter BV. et al. Caspase-3 and tissue factor expression in lipid-rich plaque macrophages: evidence for apoptosis as link between inflammation and atherothrombosis. Circulation 2004; 109: 2001-2008.
• 8 Toschi V, Gallo R, Lettino M. et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 1997; 95: 594-599.
• 9 Isner JM, Kearney M, Bortman S. et al. Apoptosis in human atherosclerosis and restenosis. Circulation 1995; 91: 2703-2711.
• 10 Clarke MC, Talib S, Figg NL. et al. Vascular smooth muscle cell apoptosis induces interleukin-1-directed inflammation: effects of hyperlipidemia-mediated inhibition of phagocytosis. Circ Res; 106: 363-372.
• 11 Katugampola SD, Davenport AP. Thromboxane receptor density is increased in human cardiovascular disease with evidence for inhibition at therapeutic concentrations by the AT(1) receptor antagonist losartan. Br J Pharmacol 2001; 134: 1385-1392.
• 12 Dogne JM, Hanson J, Pratico D. Thromboxane, prostacyclin and isoprostanes: therapeutic targets in atherogenesis. Trends Pharmacol Sci 2005; 26: 639-644.
• 13 Huang JS, Ramamurthy SK, Lin X. et al. Cell signalling through thromboxane A2 receptors. Cell Signal 2004; 16: 521-533.
• 14 Hirata M, Hayashi Y, Ushikubi F. et al. Cloning and expression of cDNA for a human thromboxane A2 receptor. Nature 1991; 349: 617-620.
• 15 Nusing RM, Hirata M, Kakizuka A. et al. Characterization and chromosomal mapping of the human thromboxane A2 receptor gene. J Biol Chem 1993; 268: 25253-25259.
• 16 Raychowdhury MK, Yukawa M, Collins LJ. et al. Alternative splicing produces a divergent cytoplasmic tail in the human endothelial thromboxane A2 receptor. J Biol Chem 1994; 269: 19256-19261.
• 17 Miggin SM, Kinsella BT. Expression and tissue distribution of the mRNAs encoding the human thromboxane A2 receptor (TP) alpha and beta isoforms. Biochim Biophys Acta 1998; 1425: 543-559.
• 18 Meja KK, Barnes PJ, Giembycz MA. Characterization of the prostanoid receptor(s) on human blood monocytes at which prostaglandin E2 inhibits lipopolysaccharide-induced tumour necrosis factor-alpha generation. Br J Pharmacol 1997; 122: 149-157.
• 19 Shenker A, Goldsmith P, Unson CG. et al. The G protein coupled to the thromboxane A2 receptor in human platelets is a member of the novel Gq family. J Biol Chem 1991; 266: 9309-9313.
• 20 Berridge MJ, Irvine RF. Inositol trisphosphate, a novel second messenger in cellular signal transduction. Nature 1984; 312: 315-321.
• 21 Massini P, Luscher EF. Some effects of ionophores for divalent cations on blood platelets. Comparison with the effects of thrombin. Biochim Biophys Acta 1974; 372: 109-121.
• 22 Feinstein MB, Fraser C. Human platelet secretion and aggregation induced by calcium ionophores. Inhibition by PGE1 and dibutyryl cyclic AMP. J Gen Physiol 1975; 66: 561-581.
• 23 Rink TJ, Sanchez A, Hallam TJ. Diacylglycerol and phorbol ester stimulate secretion without raising cytoplasmic free calcium in human platelets. Nature 1983; 305: 317-319.
• 24 Chung SH, Polgar J, Reed GL. Protein kinase C phosphorylation of syntaxin 4 in thrombin-activated human platelets. J Biol Chem 2000; 275: 25286-25291.
• 25 Hall A. Rho GTPases and the actin cytoskeleton. Science 1998; 279: 509-514.
• 26 Moers A, Wettschureck N, Gruner S. et al. Unresponsiveness of platelets lacking both Galpha(q) and Galpha(13). Implications for collagen-induced platelet activation. J Biol Chem 2004; 279: 45354-45359.
• 27 Offermanns S, Laugwitz KL, Spicher K. et al. G proteins of the G12 family are activated via thromboxane A2 and thrombin receptors in human platelets. Proc Natl Acad Sci USA 1994; 91: 504-508.
• 28 Ohkubo S, Nakahata N, Ohizumi Y. Thromboxane A2-mediated shape change: independent of Gq-phospholipase C--Ca2+ pathway in rabbit platelets. Br J Pharmacol 1996; 117: 1095-1104.
• 29 Wilson DP, Susnjar M, Kiss E. et al. Thromboxane A2-induced contraction of rat caudal arterial smooth muscle involves activation of Ca2+ entry and Ca2+ sensitization: Rho-associated kinase-mediated phosphorylation of MYPT1 at Thr-855, but not Thr-697. Biochem J 2005; 389: 763-774.
• 30 Vezza R, Habib A, FitzGerald GA. Differential signaling by the thromboxane receptor isoforms via the novel GTP-binding protein, Gh. J Biol Chem 1999; 274: 12774-1279.
• 31 Zhang S, Coso OA, Lee C. et al. Selective activation of effector pathways by brain-specific G protein beta5. J Biol Chem 1996; 271: 33575-33579.
• 32 Maier U, Babich A, Macrez N. et al. Gbeta 5gamma 2 is a highly selective activator of phospholipid-dependent enzymes. J Biol Chem 2000; 275: 13746-13754.
• 33 Vanhoutte PM, Feletou M, Taddei S. Endothelium-dependent contractions in hypertension. Br J Pharmacol 2005; 144: 449-458.
• 34 Feletou M, Verbeuren TJ, Vanhoutte PM. Endothelium-dependent contractions in SHR: a tale of prostanoid TP and IP receptors. Br J Pharmacol 2009; 156: 563-574.
• 35 Ishizuka T, Suzuki K, Kawakami M. et al. Thromboxane A2 receptor blockade suppresses intercellular adhesion molecule-1 expression by stimulated vascular endothelial cells. Eur J Pharmacol 1996; 312: 367-377.
• 36 Ishizuka T, Kawakami M, Hidaka T. et al. Stimulation with thromboxane A2 (TXA2) receptor agonist enhances ICAM-1, VCAM-1 or ELAM-1 expression by human vascular endothelial cells. Clin Exp Immunol 1998; 112: 464-470.
• 37 Ashton AW, Ware GM, Kaul DK. et al. Inhibition of tumor necrosis factor alpha-mediated NFkappaB activation and leukocyte adhesion, with enhanced endothelial apoptosis, by G protein-linked receptor (TP) ligands. J Biol Chem 2003; 278: 11858-11866.
• 38 Uehara Y, Ishimitsu T, Kimura K. et al. Regulatory effects of eicosanoids on thymidine uptake by vascular smooth muscle cells of rats. Prostaglandins 1988; 36: 847-857.
• 39 Ali S, Davis MG, Becker MW. et al. Thromboxane A2 stimulates vascular smooth muscle hypertrophy by up-regulating the synthesis and release of endogenous basic fibroblast growth factor. J Biol Chem 1993; 268: 17397-17403.
• 40 Dorn 2nd GW, Becker MW, Davis MG. Dissociation of the contractile and hyper-trophic effects of vasoconstrictor prostanoids in vascular smooth muscle. J Biol Chem 1992; 267: 24897-24905.
• 41 Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-1695.
• 42 Kobayashi T, Tahara Y, Matsumoto M. et al. Roles of thromboxane A(2) and pros-tacyclin in the development of atherosclerosis in apoE-deficient mice. J Clin Invest 2004; 114: 784-794.
• 43 Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324: 71-86.
• 44 Viles-Gonzalez JF, Fuster V, Corti R. et al. Atherosclerosis regression and TP receptor inhibition: effect of S18886 on plaque size and composition--a magnetic resonance imaging study. Eur Heart J 2005; 26: 1557-1561.
• 45 Osende JI, Shimbo D, Fuster V. et al. Antithrombotic effects of S 18886, a novel orally active thromboxane A2 receptor antagonist. J Thromb Haemost 2004; 02: 492-498.
• 46 Vilahur G, Casani L, Badimon L. A thromboxane A2/prostaglandin H2 receptor antagonist (S18886) shows high antithrombotic efficacy in an experimental model of stent-induced thrombosis. Thromb Haemost 2007; 98: 662-669.
• 47 Fiessinger JN. TAIPAID Study Group: S18886, a new specific TP receptor antagonist is safe and as effective as aspirin in inhibiting platelet aggregation in patients with peripheral arterial disease. . Eur Heart J 2004; 25: 89-90.
• 48 Ishizuka T, Matsumura K, Matsui T. et al. Ramatroban, a thromboxane A2 receptor antagonist, prevents macrophage accumulation and neointimal formation after balloon arterial injury in cholesterol-fed rabbits. J Cardiovasc Pharmacol 2003; 41: 571-578.
• 49 Ishizuka T, Matsui T, Kurita A. Ramatroban, a TP receptor antagonist, improves vascular responses to acetylcholine in hypercholesterolemic rabbits in vivo. Eur J Pharmacol 2003; 468: 27-35.
• 50 Cayatte AJ, Du Y, Oliver-Krasinski J. et al. The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arterioscler Thromb Vasc Biol 2000; 20: 1724-1728.
• 51 Belhassen L, Pelle G, Dubois-Rande JL. et al. Improved endothelial function by the thromboxane A2 receptor antagonist S 18886 in patients with coronary artery disease treated with aspirin. J Am Coll Cardiol 2003; 41: 1198-1204.
• 52 Worth NF, Berry CL, Thomas AC. et al. S18886, a selective TP receptor antagonist, inhibits development of atherosclerosis in rabbits. Atherosclerosis 2005; 183: 65-73.
• 53 Cipollone F, Rocca B, Patrono C. Cyclooxygenase-2 expression and inhibition in atherothrombosis. Arterioscler Thromb Vasc Biol 2004; 24: 246-255.
• 54 Burleigh ME, Babaev VR, Oates JA. et al. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation 2002; 105: 1816-1823.
• 55 Burleigh ME, Babaev VR, Yancey PG. et al. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in ApoE-deficient and C57BL/6 mice. J Mol Cell Cardiol 2005; 39: 443-452.
• 56 Kerr DJ, Dunn JA, Langman MJ. et al. Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. N Engl J Med 2007; 357: 360-369.
• 57 Baron JA, Sandler RS, Bresalier RS. et al. Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet 2008; 372: 1756-1764.
• 58 Egan KM, Wang M, Fries S. et al. Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation 2005; 111: 334-342.
• 59 Kleiman NS. Platelets, the cardiologist, and coronary artery disease: moving beyond aggregation. J Am Coll Cardiol 2004; 43: 1989-1991.
• 60 Huo Y, Schober A, Forlow SB. et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 2003; 09: 61-67.
• 61 Fuster V, Fayad ZA, Moreno PR. et al. Atherothrombosis and high-risk plaque: Part II: approaches by noninvasive computed tomographic/magnetic resonance imaging. J Am Coll Cardiol 2005; 46: 1209-1218.
• 62 Gelosa P, Ballerio R, Banfi C. et al. Terutroban, a Tp Receptor Antagonist, Increases Survival in Stroke-Prone Rats by Preventing Systemic Inflammation and Endothelial Dysfunction. Comparison with Aspirin and Rosuvastatin. J Pharmacol Exp Ther 2010; 334: 199-205.
• 63 Bal Dit Sollier C, Crassard I, Simoneau G. et al. Effect of the thromboxane pros-taglandin receptor antagonist terutroban on arterial thrombogenesis after repeated administration in patients treated for the prevention of ischemic stroke. Cerebrovasc Dis 2009; 28: 505-513.
• 64 A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348: 1329-1339.
• 65 Cannon CP, Harrington RA, James S. et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet 2010; 375: 283-293.
• 66 Pulcinelli FM, Biasucci LM, Riondino S. et al. COX-1 sensitivity and thromboxane A2 production in type 1 and type 2 diabetic patients under chronic aspirin treatment. Eur Heart J 2009; 30: 1279-1286.
• 67 Mortensen SB, Larsen SB, Grove EL. et al. Reduced platelet response to aspirin in patients with coronary artery disease and type 2 diabetes mellitus. Thromb Res. 2010 epub ahead of print.